USANA Health Sciences Files 8-K Report
Ticker: USNA · Form: 8-K · Filed: 2024-07-23T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: USNA
TL;DR
USANA Health Sciences dropped an 8-K on 7/23 - check financials and operations.
AI Summary
On July 23, 2024, USANA Health Sciences, Inc. filed an 8-K report detailing its financial results and other relevant information. The filing includes information on the company's operations, financial condition, and exhibits.
Why It Matters
This 8-K filing provides investors with crucial updates on USANA Health Sciences' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine SEC filing providing financial and operational updates, not indicating any immediate or significant new risks.
Key Players & Entities
- USANA HEALTH SCIENCES, INC. (company) — Registrant
- July 23, 2024 (date) — Date of Report
- Utah (location) — State of Incorporation
- Salt Lake City (location) — Principal Executive Offices City
FAQ
What is the primary purpose of this Form 8-K filing for USANA Health Sciences, Inc.?
The primary purpose of this Form 8-K filing is to report on the Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits of USANA Health Sciences, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on July 23, 2024.
In which state is USANA Health Sciences, Inc. incorporated?
USANA Health Sciences, Inc. is incorporated in Utah.
What is the business address of USANA Health Sciences, Inc.?
The business address of USANA Health Sciences, Inc. is 3838 West Parkway Boulevard, Salt Lake City, Utah 84120.
What is the SEC file number for USANA Health Sciences, Inc.?
The SEC file number for USANA Health Sciences, Inc. is 001-35024.
From the Filing
0000896264-24-000180.txt : 20240723 0000896264-24-000180.hdr.sgml : 20240723 20240723161105 ACCESSION NUMBER: 0000896264-24-000180 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240723 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240723 DATE AS OF CHANGE: 20240723 FILER: COMPANY DATA: COMPANY CONFORMED NAME: USANA HEALTH SCIENCES INC CENTRAL INDEX KEY: 0000896264 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870500306 STATE OF INCORPORATION: UT FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35024 FILM NUMBER: 241134594 BUSINESS ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 BUSINESS PHONE: 8019547100 MAIL ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. STREET 2: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 FORMER COMPANY: FORMER CONFORMED NAME: USANA INC DATE OF NAME CHANGE: 19930125 8-K 1 usna-20240723.htm 8-K usna-20240723 FALSE 0000896264 0000896264 2024-07-23 2024-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 23, 2024 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission File No.) (IRS Employer Identification No.) 3838 West Parkway Boulevard Salt Lake City , Utah 84120 (Address of principal executive offices, Zip Code) Registrant's telephone number, including area code: ( 801 ) 954-7100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share USNA New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02    Results of Operations and Financial Condition. On July 23, 2024, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its financial results for the second quarter ended June 29, 2024. The release also announced that the Company will post a document titled “Management Commentary” on the Company’s website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company’s management team, before moving directly into questions and answe